To combat the TMZ resistance due to H2AFJ upregulation in GBM, we next performed an in silico genomic-based drug discovery using the Cancer Therapeutics Response Portal (CTRP) database [27,28]. The gene discussed is H2AJ; the disease is glioblastoma.